{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:15:48Z","timestamp":1777616148636,"version":"3.51.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008176","name":"Wessex Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010790","name":"Erasmus+","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000651","name":"Leukaemia and Lymphoma Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000651","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000376","name":"British Society for Haematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000376","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute lymphoblastic leukaemia (ALL) in adults is a rare and difficult-to-treat cancer that is characterised by excess lymphoblasts in the bone marrow. Although many patients achieve remission with chemotherapy, relapse rates are high and the associated impact on survival devastating. Most patients receive chemotherapy and for those whose overall fitness supports it, the most effective treatment to date is allogeneic stem cell transplant that can improve overall survival rates in part due to a \u2018graft-versus-leukaemia\u2019 effect. However, due to the rarity of this disease, and the availability of mature B-cell antigens on the cell surface, few new cancer antigens have been identified in adult B-ALL that could act as targets to remove residual disease in first remission or provide alternative targets for escape variants if and when current immunotherapy strategies fail. We have used RT-PCR analysis, literature searches, antibody-specific profiling and gene expression microarray analysis to identify and prioritise antigens as novel targets for the treatment of adult B-ALL.<\/jats:p>","DOI":"10.1007\/s00262-020-02484-0","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T13:02:52Z","timestamp":1579698172000},"page":"867-877","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6730-367X","authenticated-orcid":false,"given":"Stephanie","family":"Jordaens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Cooksey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6788-6211","authenticated-orcid":false,"given":"Laurie","family":"Freire Boullosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3217-9917","authenticated-orcid":false,"given":"Viggo","family":"Van Tendeloo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9255-3435","authenticated-orcid":false,"given":"Evelien","family":"Smits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6362-4481","authenticated-orcid":false,"given":"Ken I.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2276-3925","authenticated-orcid":false,"given":"Kim H.","family":"Orchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0639-4541","authenticated-orcid":false,"given":"Barbara-ann","family":"Guinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,22]]},"reference":[{"issue":"3","key":"2484_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1309\/AJCPAN7BH5DNYWZB","volume":"144","author":"S Loghavi","year":"2015","unstructured":"Loghavi S, Kutok JL, Jorgensen JL (2015) B-acute lymphoblastic leukemia\/lymphoblastic lymphoma. Am J Clin Pathol 144(3):393\u2013410. https:\/\/doi.org\/10.1309\/AJCPAN7BH5DNYWZB","journal-title":"Am J Clin Pathol"},{"issue":"39","key":"2484_CR2","doi-asserted-by":"publisher","first-page":"66728","DOI":"10.18632\/oncotarget.19271","volume":"8","author":"X Zhang","year":"2017","unstructured":"Zhang X, Rastogi P, Shah B, Zhang L (2017) B lymphoblastic leukemia\/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy. Oncotarget 8(39):66728\u201366741. https:\/\/doi.org\/10.18632\/oncotarget.19271","journal-title":"Oncotarget"},{"key":"2484_CR3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.3648","author":"R Bassan","year":"2018","unstructured":"Bassan R, Bourquin JP, DeAngelo DJ, Chiaretti S (2018) New approaches to the management of adult acute lymphoblastic leukemia. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2017.77.3648","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"2484_CR4","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","volume":"27","author":"D Hoelzer","year":"2016","unstructured":"Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C, Committee EG (2016) Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5):v69\u2013v82. https:\/\/doi.org\/10.1093\/annonc\/mdw025","journal-title":"Ann Oncol"},{"issue":"2","key":"2484_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nrd2240","volume":"6","author":"CH Pui","year":"2007","unstructured":"Pui CH, Jeha S (2007) New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov 6(2):149\u2013165. https:\/\/doi.org\/10.1038\/nrd2240","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"2484_CR6","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/cncr.24862","volume":"116","author":"S Faderl","year":"2010","unstructured":"Faderl S, O'Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, Kantarjian HM (2010) Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 116(5):1165\u20131176. https:\/\/doi.org\/10.1002\/cncr.24862","journal-title":"Cancer"},{"issue":"1","key":"2484_CR7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13045-017-0516-x","volume":"10","author":"G Wei","year":"2017","unstructured":"Wei G, Wang J, Huang H, Zhao Y (2017) Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia. J Hematol Oncol 10(1):150. https:\/\/doi.org\/10.1186\/s13045-017-0516-x","journal-title":"J Hematol Oncol"},{"issue":"8","key":"2484_CR8","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gokbuget N, O'Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS (2016) Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375(8):740\u2013753. https:\/\/doi.org\/10.1056\/NEJMoa1509277","journal-title":"N Engl J Med"},{"issue":"3","key":"2484_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1177\/1060028017736539","volume":"52","author":"TZ Horvat","year":"2018","unstructured":"Horvat TZ, Seddon AN, Ogunniyi A, King AC, Buie LW, Daley RJ (2018) The ABCs of immunotherapy for adult patients with B-cell acute lymphoblastic leukemia. Ann Pharmacother 52(3):268\u2013276. https:\/\/doi.org\/10.1177\/1060028017736539","journal-title":"Ann Pharmacother"},{"key":"2484_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/asheducation-2017.1.28","volume":"1","author":"J Leonard","year":"2017","unstructured":"Leonard J (2017) Stock W (2017) Progress in adult ALL: incorporation of new agents to frontline treatment. Hematol Am Soc Hematol Educ Program 1:28\u201336. https:\/\/doi.org\/10.1182\/asheducation-2017.1.28","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"11","key":"2484_CR11","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1159\/000481946","volume":"40","author":"MA Schwarzbich","year":"2017","unstructured":"Schwarzbich MA, Witzens-Harig M (2017) Cellular immunotherapy in B-cell malignancy. Oncol Res Treat 40(11):674\u2013681. https:\/\/doi.org\/10.1159\/000481946","journal-title":"Oncol Res Treat"},{"issue":"13","key":"2484_CR12","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1002\/cncr.30624","volume":"123","author":"ME Rytting","year":"2017","unstructured":"Rytting ME, Jabbour EJ, O'Brien SM, Kantarjian HM (2017) Acute lymphoblastic leukemia in adolescents and young adults. Cancer 123(13):2398\u20132403. https:\/\/doi.org\/10.1002\/cncr.30624","journal-title":"Cancer"},{"issue":"1","key":"2484_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40266-017-0503-5","volume":"35","author":"N Gokbuget","year":"2018","unstructured":"Gokbuget N (2018) Treatment of older patients with acute lymphoblastic leukaemia. Drugs Aging 35(1):11\u201326. https:\/\/doi.org\/10.1007\/s40266-017-0503-5","journal-title":"Drugs Aging"},{"issue":"4","key":"2484_CR14","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1158\/2159-8290.CD-12-0383","volume":"3","author":"C Ma","year":"2013","unstructured":"Ma C, Cheung AF, Chodon T, Koya RC, Wu Z, Ng C, Avramis E, Cochran AJ, Witte ON, Baltimore D, Chmielowski B, Economou JS, Comin-Anduix B, Ribas A, Heath JR (2013) Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov 3(4):418\u2013429. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0383","journal-title":"Cancer Discov"},{"issue":"5","key":"2484_CR15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O'Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Tian L, Parakandi H, Gupta M, Young RM, Johnson FB, Kulikovskaya I, Liu L, Xu J, Kassim SH, Davis MM, Levine BL, Frey NV, Siegel DL, Huang AC, Wherry EJ, Bitter H, Brogdon JL, Porter DL, June CH, Melenhorst JJ (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24(5):563\u2013571. https:\/\/doi.org\/10.1038\/s41591-018-0010-1","journal-title":"Nat Med"},{"key":"2484_CR16","first-page":"16","volume":"13","author":"N Hardwick","year":"2013","unstructured":"Hardwick N, Buchan S, Ingram W, Khan G, Vittes G, Rice J, Pulford K, Mufti G, Stevenson F, Guinn BA (2013) An analogue peptide from the cancer\/testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide. Cancer Immun 13:16","journal-title":"Cancer Immun"},{"issue":"2","key":"2484_CR17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1365-2141.2007.06892.x","volume":"140","author":"BA Guinn","year":"2008","unstructured":"Guinn BA, Bullinger L, Thomas NS, Mills KI, Greiner J (2008) SSX2IP expression in acute myeloid leukaemia: an association with mitotic spindle failure in t(8;21), and cell cycle in t(15;17) patients. Br J Haematol 140(2):250\u2013251. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06892.x","journal-title":"Br J Haematol"},{"issue":"5","key":"2484_CR18","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1182\/blood-2008-09-178848","volume":"113","author":"B Guinn","year":"2009","unstructured":"Guinn B, Greiner J, Schmitt M, Mills KI (2009) Elevated expression of the leukemia-associated antigen SSX2IP predicts survival in acute myeloid leukemia patients who lack detectable cytogenetic rearrangements. Blood 113(5):1203\u20131204. https:\/\/doi.org\/10.1182\/blood-2008-09-178848","journal-title":"Blood"},{"issue":"6","key":"2484_CR19","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M (2017) Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J 7(6):e577. https:\/\/doi.org\/10.1038\/bcj.2017.53","journal-title":"Blood Cancer J"},{"issue":"11","key":"2484_CR20","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1038\/sj.leu.2402732","volume":"16","author":"SP Adams","year":"2002","unstructured":"Adams SP, Sahota SS, Mijovic A, Czepulkowski B, Padua RA, Mufti GJ, Guinn BA (2002) Frequent expression of HAGE in presentation chronic myeloid leukaemias. Leukemia 16(11):2238\u20132242. https:\/\/doi.org\/10.1038\/sj.leu.2402732","journal-title":"Leukemia"},{"issue":"4","key":"2484_CR21","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.bbrc.2005.08.024","volume":"335","author":"BA Guinn","year":"2005","unstructured":"Guinn BA, Bland EA, Lodi U, Liggins AP, Tobal K, Petters S, Wells JW, Banham AH, Mufti GJ (2005) Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. Biochem Biophys Res Commun 335(4):1293\u20131304. https:\/\/doi.org\/10.1016\/j.bbrc.2005.08.024","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2484_CR22","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.18632\/oncotarget.23380","volume":"9","author":"LF Boullosa","year":"2018","unstructured":"Boullosa LF, Savaliya P, Bonney S, Orchard L, Wickenden H, Lee C, Smits E, Banham AH, Mills KI, Orchard K, Guinn BA (2018) Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia. Oncotarget 9(3):3853\u20133866. https:\/\/doi.org\/10.18632\/oncotarget.23380","journal-title":"Oncotarget"},{"issue":"17","key":"2484_CR23","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15(17):5323\u20135337. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0737","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2484_CR24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/ijc.20170","volume":"110","author":"AP Liggins","year":"2004","unstructured":"Liggins AP, Guinn BA, Hatton CS, Pulford K, Banham AH (2004) Serologic detection of diffuse large B-cell lymphoma-associated antigens. Int J Cancer 110(4):563\u2013569. https:\/\/doi.org\/10.1002\/ijc.20170","journal-title":"Int J Cancer"},{"issue":"4","key":"2484_CR25","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/j.1365-2133.2009.09568.x","volume":"162","author":"S Ghafouri-Fard","year":"2010","unstructured":"Ghafouri-Fard S, Abbasi A, Moslehi H, Faramarzi N, Taba Taba Vakili S, Mobasheri MB, Modarressi MH (2010) Elevated expression levels of testis-specific genes TEX101 and SPATA19 in basal cell carcinoma and their correlation with clinical and pathological features. Br J Dermatol 162(4):772\u2013779. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09568.x","journal-title":"Br J Dermatol"},{"key":"2484_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4137\/BIC.S28378","volume":"7","author":"G Khan","year":"2015","unstructured":"Khan G, Brooks SE, Mills KI, Guinn BA (2015) Infrequent expression of the cancer-testis antigen, PASD1, in ovarian cancer. Biomark Cancer 7:31\u201338. https:\/\/doi.org\/10.4137\/BIC.S28378","journal-title":"Biomark Cancer"},{"issue":"10","key":"2484_CR27","doi-asserted-by":"publisher","first-page":"e0140483","DOI":"10.1371\/journal.pone.0140483","volume":"10","author":"SE Brooks","year":"2015","unstructured":"Brooks SE, Bonney SA, Lee C, Publicover A, Khan G, Smits EL, Sigurdardottir D, Arno M, Li D, Mills KI, Pulford K, Banham AH, van Tendeloo V, Mufti GJ, Rammensee HG, Elliott TJ, Orchard KH, Guinn BA (2015) Application of the pMHC array to characterise tumour antigen specific T cell populations in leukaemia patients at disease diagnosis. PLoS ONE 10(10):e0140483. https:\/\/doi.org\/10.1371\/journal.pone.0140483","journal-title":"PLoS ONE"},{"issue":"7","key":"2484_CR28","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1074\/mcp.R600016-MCP200","volume":"6","author":"M Caron","year":"2007","unstructured":"Caron M, Choquet-Kastylevsky G, Joubert-Caron R (2007) Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics 6(7):1115\u20131122. https:\/\/doi.org\/10.1074\/mcp.R600016-MCP200","journal-title":"Mol Cell Proteomics"},{"key":"2484_CR29","first-page":"77","volume-title":"Tumour markers research perspectives","author":"BA Guinn","year":"2007","unstructured":"Guinn BA, Tobal K (2007) Tumour antigens as markers of minimal residual disease in acute myeloid leukaemia. In: Sinise GA (ed) Tumour markers research perspectives. Nova Science Publishers Inc, New York, pp 77\u201390"},{"issue":"7","key":"2484_CR30","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1002\/cncr.26486","volume":"118","author":"C Zou","year":"2012","unstructured":"Zou C, Shen J, Tang Q, Yang Z, Yin J, Li Z, Xie X, Huang G, Lev D, Wang J (2012) Cancer-testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis. Cancer 118(7):1845\u20131855. https:\/\/doi.org\/10.1002\/cncr.26486","journal-title":"Cancer"},{"issue":"4","key":"2484_CR31","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1677\/erc.1.00766","volume":"11","author":"P Carter","year":"2004","unstructured":"Carter P, Smith L, Ryan M (2004) Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer 11(4):659\u2013687. https:\/\/doi.org\/10.1677\/erc.1.00766","journal-title":"Endocr Relat Cancer"},{"key":"2484_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/1179299X19830977","author":"K Grayson","year":"2019","unstructured":"Grayson K, Gregory E, Khan G, Guinn BA (2019) Urine biomarkers for the early detection of ovarian cancer\u2014Are we there yet? Biomark Cancer. https:\/\/doi.org\/10.1177\/1179299X19830977","journal-title":"Biomark Cancer"},{"issue":"6","key":"2484_CR33","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/sj.leu.2404234","volume":"20","author":"AJ Knights","year":"2006","unstructured":"Knights AJ, Weinzierl AO, Flad T, Guinn BA, Mueller L, Mufti GJ, Stevanovic S, Pawelec G (2006) A novel MHC-associated proteinase 3 peptide isolated from primary chronic myeloid leukaemia cells further supports the significance of this antigen for the immunotherapy of myeloid leukaemias. Leukemia 20(6):1067\u20131072. https:\/\/doi.org\/10.1038\/sj.leu.2404234","journal-title":"Leukemia"},{"key":"2484_CR34","doi-asserted-by":"crossref","unstructured":"Jordaens S, Cooksey L, Bonney S, Orchard L, Cotinho M, Van Tendeloo V, Mills KI, Orchard K, Guinn B (2020) Sero-profiling identifies new targets for the treatment of adults with B-cell acute lymphoblastic leukaemia. British Journal of Haematology, In Press.","DOI":"10.1111\/bjh.16407"},{"issue":"1 Suppl","key":"2484_CR35","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.1016\/j.bbmt.2011.11.011","volume":"18","author":"M Chapman","year":"2012","unstructured":"Chapman M, Warren EH 3rd, Wu CJ (2012) Applications of next-generation sequencing to blood and marrow transplantation. Biol Blood Marrow Transplant 18(1 Suppl):S151\u2013160. https:\/\/doi.org\/10.1016\/j.bbmt.2011.11.011","journal-title":"Biol Blood Marrow Transplant"},{"key":"2484_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12935-016-0326-1","volume":"16","author":"H Garg","year":"2016","unstructured":"Garg H, Suri P, Gupta JC, Talwar GP, Dubey S (2016) Survivin: a unique target for tumor therapy. Cancer Cell Int 16:49. https:\/\/doi.org\/10.1186\/s12935-016-0326-1","journal-title":"Cancer Cell Int"},{"issue":"12","key":"2484_CR37","first-page":"3683","volume":"9","author":"L Tamagnone","year":"1994","unstructured":"Tamagnone L, Lahtinen I, Mustonen T, Virtaneva K, Francis F, Muscatelli F, Alitalo R, Smith CI, Larsson C, Alitalo K (1994) BMX, a novel nonreceptor tyrosine kinase gene of the BTK\/ITK\/TEC\/TXK family located in chromosome Xp222. Oncogene 9(12):3683\u20133688","journal-title":"Oncogene"},{"issue":"49","key":"2484_CR38","doi-asserted-by":"publisher","first-page":"5651","DOI":"10.1038\/sj.onc.1203958","volume":"19","author":"Y Qiu","year":"2000","unstructured":"Qiu Y, Kung HJ (2000) Signaling network of the Btk family kinases. Oncogene 19(49):5651\u20135661. https:\/\/doi.org\/10.1038\/sj.onc.1203958","journal-title":"Oncogene"},{"issue":"2","key":"2484_CR39","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3109\/08830185.2012.663838","volume":"31","author":"B Cenni","year":"2012","unstructured":"Cenni B, Gutmann S, Gottar-Guillier M (2012) BMX and its role in inflammation, cardiovascular disease, and cancer. Int Rev Immunol 31(2):166\u2013173. https:\/\/doi.org\/10.3109\/08830185.2012.663838","journal-title":"Int Rev Immunol"},{"issue":"10","key":"2484_CR40","doi-asserted-by":"publisher","first-page":"6014","DOI":"10.4049\/jimmunol.1002813","volume":"186","author":"M Gottar-Guillier","year":"2011","unstructured":"Gottar-Guillier M, Dodeller F, Huesken D, Iourgenko V, Mickanin C, Labow M, Gaveriaux S, Kinzel B, Mueller M, Alitalo K, Littlewood-Evans A, Cenni B (2011) The tyrosine kinase BMX is an essential mediator of inflammatory arthritis in a kinase-independent manner. J Immunol 186(10):6014\u20136023. https:\/\/doi.org\/10.4049\/jimmunol.1002813","journal-title":"J Immunol"},{"issue":"14","key":"2484_CR41","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1158\/0008-5472.CAN-11-1070","volume":"72","author":"T Holopainen","year":"2012","unstructured":"Holopainen T, Lopez-Alpuche V, Zheng W, Heljasvaara R, Jones D, He Y, Tvorogov D, D'Amico G, Wiener Z, Andersson LC, Pihlajaniemi T, Min W, Alitalo K (2012) Deletion of the endothelial Bmx tyrosine kinase decreases tumor angiogenesis and growth. Cancer Res 72(14):3512\u20133521. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-1070","journal-title":"Cancer Res"},{"issue":"13","key":"2484_CR42","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1158\/0008-5472.CAN-09-4610","volume":"70","author":"B Dai","year":"2010","unstructured":"Dai B, Chen H, Guo S, Yang X, Linn DE, Sun F, Li W, Guo Z, Xu K, Kim O, Kong X, Melamed J, Qiu S, Chen H, Qiu Y (2010) Compensatory upregulation of tyrosine kinase Etk\/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. Cancer Res 70(13):5587\u20135596. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-4610","journal-title":"Cancer Res"},{"issue":"22","key":"2484_CR43","doi-asserted-by":"publisher","first-page":"5916","DOI":"10.1016\/j.bmcl.2008.07.062","volume":"18","author":"W Hur","year":"2008","unstructured":"Hur W, Velentza A, Kim S, Flatauer L, Jiang X, Valente D, Mason DE, Suzuki M, Larson B, Zhang J, Zagorska A, Didonato M, Nagle A, Warmuth M, Balk SP, Peters EC, Gray NS (2008) Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. Bioorg Med Chem Lett 18(22):5916\u20135919. https:\/\/doi.org\/10.1016\/j.bmcl.2008.07.062","journal-title":"Bioorg Med Chem Lett"},{"issue":"7","key":"2484_CR44","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1021\/cb4000629","volume":"8","author":"F Liu","year":"2013","unstructured":"Liu F, Zhang X, Weisberg E, Chen S, Hur W, Wu H, Zhao Z, Wang W, Mao M, Cai C, Simon NI, Sanda T, Wang J, Look AT, Griffin JD, Balk SP, Liu Q, Gray NS (2013) Discovery of a selective irreversible BMX inhibitor for prostate cancer. ACS Chem Biol 8(7):1423\u20131428. https:\/\/doi.org\/10.1021\/cb4000629","journal-title":"ACS Chem Biol"},{"key":"2484_CR45","doi-asserted-by":"publisher","first-page":"e1409","DOI":"10.1038\/cddis.2014.343","volume":"5","author":"W Guo","year":"2014","unstructured":"Guo W, Liu R, Bhardwaj G, Yang JC, Changou C, Ma AH, Mazloom A, Chintapalli S, Xiao K, Xiao W, Kumaresan P, Sanchez E, Yeh CT, Evans CP, Patterson R, Lam KS, Kung HJ (2014) Targeting Btk\/Etk of prostate cancer cells by a novel dual inhibitor. Cell Death Dis 5:e1409. https:\/\/doi.org\/10.1038\/cddis.2014.343","journal-title":"Cell Death Dis"},{"issue":"1","key":"2484_CR46","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1200\/JCO.2012.44.4281","volume":"31","author":"A Wiestner","year":"2013","unstructured":"Wiestner A (2013) Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 31(1):128\u2013130. https:\/\/doi.org\/10.1200\/JCO.2012.44.4281","journal-title":"J Clin Oncol"},{"issue":"12","key":"2484_CR47","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","volume":"3","author":"SE Coutre","year":"2019","unstructured":"Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM (2019) Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv 3(12):1799\u20131807. https:\/\/doi.org\/10.1182\/bloodadvances.2018028761","journal-title":"Blood Adv"},{"issue":"4","key":"2484_CR48","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR (2016) Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 374(4):323\u2013332. https:\/\/doi.org\/10.1056\/NEJMoa1509981","journal-title":"N Engl J Med"},{"issue":"6","key":"2484_CR49","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369(6):507\u2013516. https:\/\/doi.org\/10.1056\/NEJMoa1306220","journal-title":"N Engl J Med"},{"issue":"11","key":"2484_CR50","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1158\/2159-8290.CD-12-0208","volume":"2","author":"H Geng","year":"2012","unstructured":"Geng H, Brennan S, Milne TA, Chen WY, Li Y, Hurtz C, Kweon SM, Zickl L, Shojaee S, Neuberg D, Huang C, Biswas D, Xin Y, Racevskis J, Ketterling RP, Luger SM, Lazarus H, Tallman MS, Rowe JM, Litzow MR, Guzman ML, Allis CD, Roeder RG, Muschen M, Paietta E, Elemento O, Melnick AM (2012) Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov 2(11):1004\u20131023. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0208","journal-title":"Cancer Discov"},{"issue":"5","key":"2484_CR51","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3892\/br.2018.1077","volume":"8","author":"D Li","year":"2018","unstructured":"Li D, Hu C, Li H (2018) Survivin as a novel target protein for reducing the proliferation of cancer cells. Biomed Rep 8(5):399\u2013406. https:\/\/doi.org\/10.3892\/br.2018.1077","journal-title":"Biomed Rep"},{"issue":"D1","key":"2484_CR52","doi-asserted-by":"publisher","first-page":"D881","DOI":"10.1093\/nar\/gky1076","volume":"47","author":"FO Bagger","year":"2019","unstructured":"Bagger FO, Kinalis S, Rapin N (2019) BloodSpot: a database of healthy and malignant haematopoiesis updated with purified and single cell mRNA sequencing profiles. Nucleic Acids Res 47(D1):D881\u2013D885. https:\/\/doi.org\/10.1093\/nar\/gky1076","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"2484_CR53","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2141.1996.tb00091.x","volume":"94","author":"J Kaukonen","year":"1996","unstructured":"Kaukonen J, Lahtinen I, Laine S, Alitalo K, Palotie A (1996) BMX tyrosine kinase gene is expressed in granulocytes and myeloid leukaemias. Br J Haematol 94(3):455\u2013460","journal-title":"Br J Haematol"},{"issue":"9","key":"2484_CR54","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1182\/blood-2016-06-722900","volume":"129","author":"E Kim","year":"2017","unstructured":"Kim E, Hurtz C, Koehrer S, Wang Z, Balasubramanian S, Chang BY, Muschen M, Davis RE, Burger JA (2017) Ibrutinib inhibits pre-BCR(+) B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood 129(9):1155\u20131165. https:\/\/doi.org\/10.1182\/blood-2016-06-722900","journal-title":"Blood"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02484-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-020-02484-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02484-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:15:17Z","timestamp":1611188117000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-020-02484-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["2484"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02484-0","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,22]]},"assertion":[{"value":"8 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}